Clinical Research
Along with normal clinical service, wide range of clinical trials also provided in our center
We collaborate with academics and clinicians in Department of Medicine, Department of Surgery, Department of Clinical Oncology and Clinical Trial Centre in conducting cutting-edge clinical trials to cancer patients.
We are actively recruiting patient to participate in the following clinical trials
Please send referral letter to medicaloncology@hku.hk if interested
Recruiting Clinical Trials
Liver Cancer
Protocol Number
Protocol Title
Experimental Agent
Principle Investigator
CA224-106
A Phase 1/2, Safety Confirmation and Double-blind, Placebo-controlled, Randomized Study of Relatlimab in Combination with Nivolumab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma (RELATIVITY-106)
Relatilimab + Nivolumab + Bevacizumab
CO44668 (IMbrave152)
A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluation Atezolizumab and Bevacizumab, with or without Tiragolumab, in Patients with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Nivolumab + Bevacizumab +/- Tiragolumab
OTX-2002-101
A Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene.
OTX-2002
Breast Cancer
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
OBI-822-011
The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer
OBI-822, OBI-821
VS
Placebo
GS-US-592-6173 (Ascent -04)
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
Sacituzumab Govitecan-hziy (SG) + Pembrolizumab
VS
Pembrolizumab + Treatment of Physician's Choice (TPC)
GS-US-586-6144
A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer
Magrolimab + Nab-Paclitaxel or Paclitaxe
VS
Nab-Paclitaxel or Paclitaxe
Lung Cancer
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
MK-7684A-003
A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer
MK-7684A (vibostolimab + pembrolizumab)
GS-US-576-6220
An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations
Sacituzumab Govitecan-hziy (SG)
BA 3011-002
A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor
BA3011
VS
BA3011 +PD-1 inhibitor
475-0708 MT Lung
A Phase 2 Open-label Single-arm Study to Evaluate the Combination of Pembrolizumab, Lenvatinib and Chemotherapy in Non-small Cell Lung Cancer (NSCLC) Harbouring Targetable Mutation and Failed Standard Tyrosine Kinase Inhibitors
Pembrolizumab + Lenvatinib + Pemetrexed + Carboplatin
GS-US-624-6376
(Velocity 01/02)
A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients with Lung Cancer
Novel Treatment combination
Genitourinary
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
BO42843
A Phase III, Double-Blind, multicenter, randomized study of Atezolizumab ( Anti-PD-L1 antibody) versus Placebo as adjuvant therapy in patient with high-risk muscle-invasive Bladder cancer who are ctDNA positive following Cystectomy
Atezolizumab
vs
Placebo
A Phase 3, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotheraphy in Participants with MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC) (SAMETA)
durvalumab and savolitinib
vs
durvalumab
vs
sunitinib
Colorectal Cancer
Protocol Number
Protocol Title
Experimental Agent
Principle Investigator
GS-US-587-6156
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
Bevacizumab + FOLFIRI +/- Magrolimab
Other Solid Tumor
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
STARTRK-2
An Open-Label, Multicenter, Global Phase2 Basket Study of Entrectinib for the treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Entrectinib
IMMU-132-11
A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors
Sacituzumab Govitecan-hziy (SG)
TIDENT-1
(TPX-0005-01)
Phase 2 Study
NTRK1/2/3-/ROS-1/ALK-rearranged solid tumors
Repotrectinib
BA3021-001
A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)
BA3021
VS
BA3021 + PD-1 inhibitor
Phase 1 Study
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
A001 (Abrele)
A Phase 1, first-in-human study of ARB202, bispecific antibody to CDH17 and CD3 in advanced gastrointestinal malignancies
ARB202
NEI01-20001
A 2-part, First-in-patient, Open-label, Dose-escalation and Expansion Cohort Study of NEI-01 as Monotherapy in Patients With Advanced Solid Tumors or Relapsed/Refractory Acute Myeloid Leukemia
NEI-01
BA3021-001
A phase 1/2 dose escalation and dose expansion study of BA3021 alone and in combination with nivolumab in patients with advanced solid tumors
BA3021
+/-
nivolumab
4003.1
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors
HBM4003
RLY-4008-101
A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors
RLY-4008
Gastrointestinal Cancer
Protocol Number
Protocol Title
Experimental Agent
Principle Investigator
STAR-221
A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously-Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
Domvanalimab + Zimberelimab + Chemotherpay
VS
Nivolumab + Chemotherapy
Bile Duct Cancer
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
Upcoming...
Pancreatic Cancer
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
Upcoming...